文献速递妇产影像技术与安全

孕妇接种COVID-19疫苗的免疫原性与反应原性评估

Evaluation of immunogenicity and reactogenicity of COVID-19 vaccines in pregnant women.
PubMed 文献 · Ultrasound Obstet Gynecol · 2022-01-01

该队列研究纳入67名孕妇和79名非孕妇评估免疫原性,另纳入108名孕妇和116名非孕妇评估反应原性;按英国推荐的12周间隔接种。孕妇接种两剂mRNA疫苗后2-6周S抗体几何平均浓度显著低于非孕妇;孕妇报告的不良事件较少。

要点

  • 按12周间隔接种两剂mRNA疫苗后,孕妇2-6周S抗体水平显著低于非孕妇。
  • 感染过SARS-CoV-2的孕妇接种一剂后即可产生强抗体应答,无论妊娠状态。
  • 孕妇接种第一剂后疲劳和寒战报告率较低,第二剂后全身不适报告率较低。

核心结论

  • 按英国推荐的12周间隔接种两剂mRNA COVID-19疫苗后,孕妇抗体应答低于非孕妇;既往感染者接种一剂后无论妊娠状态均产生强抗体应答;孕妇报告的不良事件较少。

研究设计与样本

  • 队列研究,纳入2021年4月至9月接种COVID-19疫苗的孕妇;免疫原性分析67名孕妇(66名接种mRNA疫苗)和79名非孕妇(50名接种mRNA疫苗);反应原性分析108名孕妇和116名非孕妇;按当地疫苗接种中心可用疫苗种类接种,采用12周间隔方案。

诊断标准与关键数值

  • 免疫原性通过检测SARS-CoV-2核衣壳蛋白(N)和刺突蛋白(S)抗体滴度评估,采血时间点为每剂接种后特定时间。
  • mRNA疫苗接种后2-6周,感染未孕妇女的S抗体几何平均浓度在第一剂后无显著差异,第二剂后显著低于非孕妇。
  • 孕妇中,既往感染与第二剂后2-6周抗体水平较高相关。

局限性

  • 原文结论指出这些发现应在更大规模的对照研究中进一步探讨。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in pregnancy is associated with increased risk of adverse maternal and perinatal outcomes. Vaccines are highly effective at preventing severe coronavirus disease 2019 (COVID-19), but there are limited data on COVID-19 vaccines in pregnancy. This study aimed to investigate the reactogenicity and immunogenicity of COVID-19 vaccines in pregnant women when administered according to the 12-week-interval dosing schedule recommended in the UK.

METHODS: This was a cohort study of pregnant women receiving COVID-19 vaccination between April and September 2021. The outcomes were immunogenicity and reactogenicity after COVID-19 vaccination. Pregnant women were recruited by phone, e-mail and/or text and were vaccinated according to vaccine availability at their local vaccination center. For immunogenicity assessment, blood samples were taken at specific timepoints after each dose to evaluate nucleocapsid protein (N) and spike protein (S) antibody titers. The comparator group comprised non-pregnant female healthcare workers in the same age group who were vaccinated as part of the national immunization program in a contemporaneous longitudinal cohort study. Longitudinal changes in serum antibody titers and association with pregnancy status were assessed using a two-step regression approach. Reactogenicity assessment in pregnant women was undertaken using an online questionnaire. The comparator group comprised non-pregnant women aged 18-49 years who had received two vaccine doses in primary care. The association of pregnancy status with reactogenicity was assessed using logistic regression analysis.

RESULTS: Overall, 67 pregnant women, of whom 66 had received a mRNA vaccine, and 79 non-pregnant women, of whom 50 had received a mRNA vaccine, were included in the immunogenicity study. Most (61.2%) pregnant women received their first vaccine dose in the third trimester, while 3.0% received it in the first trimester and 35.8% in the second trimester. SARS-CoV-2 S-antibody geometric mean concentrations after mRNA vaccination were not significantly different at 2-6 weeks after the first dose but were significantly lower at 2-6 weeks after the second dose in infection-naïve pregnant compared with non-pregnant women. In pregnant women, prior infection was associated with higher antibody levels at 2-6 weeks after the second vaccine dose. Reactogenicity analysis included 108 pregnant women and 116 non-pregnant women. After the first dose, tiredness and chills were reported less commonly in pregnant compared with non-pregnant women (P = 0.043 and P = 0.029, respectively). After the second dose, feeling generally unwell was reported less commonly (P = 0.046) in pregnant compared with non-pregnant women.

CONCLUSIONS: Using an extended 12-week interval between vaccine doses, antibody responses after two doses of mRNA COVID-19 vaccine were found to be lower in pregnant compared with non-pregnant women. Strong antibody responses were achieved after one dose in previously infected women, regardless of pregnancy status. Pregnant women reported fewer adverse events after both the first and second dose of vaccine. These findings should now be addressed in larger controlled studies. © 2022 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Blakeway H, Amin-Chowdhury Z, Prasad S, et al. Evaluation of immunogenicity and reactogenicity of COVID-19 vaccines in pregnant women. Ultrasound Obstet Gynecol. 2022. PMID: 36318630. doi:10.1002/uog.26050

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。